REGN Stock Analysis — Regeneron Pharmaceuticals
Sector: Healthcare
AI Verdict
Regeneron is cheap for the sector at 14.3x forward earnings, but with just 4.5% expected EPS growth, you're betting that its R&D moat will deliver new winners to justify even this low multiple.
Competitive Moat
Regeneron specializes in monoclonal antibody therapies and leverages its proprietary VelociSuite platform to rapidly discover and develop new biologics. This integrated R&D engine gives it a defensible edge in speed and efficiency over traditional pharma pipelines.
Summary
RSI at 19.3 signals extremely oversold territory for a stock with a 25.39% 1-year return.
Where It Stands
Regeneron trades at 14.3x next year's earnings versus a healthcare median of 22x, with a 1-year return of 25.39% and an RSI of 19.3 indicating deep oversold conditions.
Key Metrics
- RSI: 19.3 — Oversold
- Trailing P/E: 15.0x
- Forward P/E: 14.3x
- PEG Ratio: 3.32
- Earnings Growth: +0.0%
- Revenue Growth: +0.1%
- Market Cap: $64.5B
- Dividend Yield: 0.01%
- 1-Year Return: 25.39%
- 52-Week High: $821.11
- 52-Week Low: $476.49
Analyst Consensus
30 Buy · 8 Hold · 0 Sell (38 analysts)
Bull Case
You're paying just 14.3x forward earnings for a company that outperformed the market with a 25.39% 1-year return and a proprietary drug discovery platform.
Bear Case
With forward EPS growth at only 4.5% and a PEG ratio of 3.32, any P/E re-rating to the sector median could mean a 35% drop from current multiples.
Catalyst to Watch
Watch for clinical trial readouts or FDA decisions on pipeline drugs, as positive results could justify the current valuation despite slow earnings growth.